Showing posts with label genetics. Show all posts
Showing posts with label genetics. Show all posts

Jul 26, 2011

Giornata Mondiale delle Epatiti: 28 Luglio

Epatite: colpisce una persona su dodici.

Di epatiti virali, con un occhio in particolare all’epatite C e all’epatite B, si parlerà in tutto il mondo il 28 luglio, in occasione del World Hepatitis Day (la Giornata Mondiale delle Epatiti).
L’evento è organizzato dal 2008 dalla World Hepatitis Alliance, un’organizzazione internazionale no profit che raggruppa un gran numero di associazioni e istituzioni e dà voce a oltre 500 milioni di persone che convivono nel mondo con epatite B ed epatite Ccronica.
L’iniziativa è promossa in collaborazione con l’OMS, che nel 2010 ha dichiarato le epatiti emergenza sanitaria globale e ha chiesto ufficialmente a tutti i governi di farsi carico di attività e campagne volte a fronteggiare il problema.

L’obiettivo principale di questa edizione del World Hepatitis Day è proprio quello di far conoscere quanto più possibile le epatiti e soprattutto di informare i cittadini di tutto il mondo sulla pericolosità di queste patologie. Nonostante i numeri dell’epidemia, che colpisce un individuo su dodici, gran parte delle persone non conosce le epatiti virali, non sa come si contraggono e come si possono prevenire né sa di esserne affetto.
Non a caso la World Hepatitis Alliance focalizza la sua comunicazione sul messaggio “Am I number 12?” ("Sono io il numero 12?").
Questa dilagante superficialità fa sì che in gran parte dei casi si arrivi ad una diagnosi tardiva.

L’importanza di iniziative come il World Hepatitis Day risiede, quindi, proprio nel suo obiettivo dichiarato: informare e sensibilizzare, perché “le epatiti colpiscono chiunque. In qualsiasi parte del mondo”.

Fonte: Paginemediche.it

Feb 15, 2010

First Illumina HiSeq Machines Advertised

News: the Illumina HiSeq can produce 200 gigabases (Gb) of sequence data and 2 billion reads per run. When it was launched we knew that BGI in China had signed an agreement to buy 128 of these machines but no-one has fessed up to owning one just yet.

Things might have changed today.

Two updates to the map of high-throughput sequencers, one hot on the heels of the other are both advertising HiSeq capability in Europe. GATC and DNAvision, both service companies have updated the map to say they have a HiSeq machine ready and waiting to service customers. Their corporate websites are a bit less clear on whether it has actually arrived yet, indicating probably that the HiSeq has just been ordered.

Jan 16, 2010

Association between Type 2 Diabetes Loci and Measures of Fatness

Type 2 diabetes (T2D) is a metabolic disorder characterized by disturbances of carbohydrate, fat and protein metabolism and insulin resistance.

The majority of T2D patients are obese and obesity by itself may be a cause of insulin resistance. Our aim was to evaluate whether the recently identified T2D risk alleles are associated with human measures of fatness as characterized with Dual Energy X-ray Absorptiometry (DEXA).

Nine single nucleotide polymorphisms (SNPs) in the CDKN2AB, CDKAL1, FTO, HHEX, IGF2BP2,KCNJ11, PPARG, SLC30A8 and TCF7L2 genes were genotyped.

Linear regression was used to study association between individual SNPs and the combined allelic risk score with body mass index (BMI), fat mass index (FMI), fat percentage (FAT), waist circumference (WC) and waist to hip ratio (WHR).

Significant association was observed between rs8050136 (FTO) and BMI (p = 0.003), FMI (p = 0.007) and WC (p = 0.03); fat percentage was borderline significant (p = 0.053). No other SNPs alone or combined in a risk score demonstrated significant association to the measures of fatness.

From the recently identified T2D risk variants only the risk variant of theFTO gene (rs8050136) showed statistically significant association with BMI, FMI, and WC.

Jan 15, 2010

Investigation of TNFA 308G > A and TNFB 252G > A polymorphisms in genetic susceptibility to migraine.

J Neurol. 2009 Dec 25; Ghosh J, Joshi G, Pradhan S, Mittal B look for the association of tumor necrosis factor (TNF) gene polymorphisms (TNFA 308G > A, and TNFB 252G > A) in genetic susceptibility to migraine. The pathogenesis of migraine involves many immune-mediated mechanisms in the vascular endothelium. TNF, being a potent immunomodulator and pro-inflammatory cytokine, is suggested to be involved in inflammatory reactions leading to migraine attacks. A total of 216 normotensive migraine patients, 160 tension type headache (TTH) patients and 216 healthy controls (HC) were recruited in the study. The genetic polymorphisms were investigated through SNP association analysis using a matched case control migraine population. Genotyping of TNFA 308G > A polymorphism and TNFB 252G > A was done using ARMS PCR and PCR-RFLP, respectively. A borderline association was observed in TNFA 308GA genotype in migraine patients versus HC (p = 0.043; OR = 1.763; 95% CI = 1.019-3.051). After sub-grouping migraine into migraine with aura (MA) or without aura, significant difference at genotypic (p = 0.015; OR = 2.293; 95% CI = 1.172-4.487) as well as allelic (p = 0.035; OR = 1.955; 95% CI = 1.047-3.651) level was evident. The difference was even more significant in female MA at genotypic (p = 0.006; OR = 2.901; 95% CI = 1.361-6.181) and allelic level (p = 0.017; OR = 2.318; 95% CI = 1.159-4.635) as well as for A allele carriers in MA [p value = 0.020; OR = 2.205 (1.132-4.295)] and female MA (p value = 0.008; OR = 2.741; CI = 1.297-5.792). No association of TNFB252G > A was observed in migraine patients or any subgroups. We did not find any association of TNFA or TNFB gene polymorphisms with TTH. In conclusion, the TNFA 308G > A polymorphism was found to be associated with MA, particularly in females, whereas we could not find any association of TNFB 252G > A polymorphism in genetic susceptibility to migraine on comparing the migraine patients with HC or TTH patients.

Jan 3, 2010

Institute for Personalized Medicine

Personalized Therapy for Each Patient

Fox Chase's new Institute for Personalized Medicine is on the forefront of a transformation in cancer care. Unlike the traditional method of delivering care, this approach will base treatment on the genetic makeup of an individual patient's tumor, making the "one-size-fits-all" approach to cancer therapy a thing of the past. Through the Institute for Personalized Medicine, our doctors and researchers are using leading edge technology to expand the understanding of cancer genetics, develop clinical trials of new treatments, and match emerging drug treatments to the unique genetics of individual patient tumors.

The immediate objective of the Institute for Personalized Medicine is to sequence exons from genes known to impact key, targetable, signaling pathways in patients with metastatic disease.

Customized Oncology

"Personalized medicine is truly transformational," says Jeff Boyd, senior vice president and chief scientific officer. "It's impossible to overstate this inflection point that cancer medicine is entering. The whole premise of how cancers are treated becomes not the tissue of origin, or how it looks under a microscope, how it looks to the surgeon, how it looks to the pathologist, but how it looks to the DNA sequencer," Boyd says.

The Institute for Personalized Medicine will build on Fox Chase's already substantialBiosample Repository and Tumor Bank to add an additional layer of new knowledge about the genetic information in individual patient tumors. Fox Chase will also use this information to accelerate the development of new cancer treatments through collaboration with its highly regarded Phase 1 Clinical Trials Program, which tests a broad spectrum of novel cancer therapeutics in patients with advanced cancer.

Vision

Our vision is one in which at the time of diagnosis and again at disease progression, a patient's cancer will be sequenced either for selected genes of interest or the entire genome. The resultant information will be housed in a searchable database, thereby allowing patients to be matched to particular drugs based upon mechanism of action, regardless of the phase of clinical trial. Updated eligibility criteria will no longer state the requirement for a given disease but instead will articulate a far more sophisticated paradigm focusing on pathway activation, gene amplification, gene mutation, or combinations thereof.

Jan 1, 2010

Homosexuality and genetics

Study shows male homosexuality can be explained through a specific model of Darwinian evolution.

Reporting in PLoS ONE, an Italian research team, consisting of Andrea Camperio Ciani and Giovanni Zanzotto at the University of Padova and Paolo Cermelli at the University of Torino, found that the evolutionary origin and maintenance of male homosexuality in human populations could be explained by a model based around the idea of sexually antagonistic selection, in which genetic factors spread in the population by giving a reproductive advantage to one sex while disadvantaging the other.

Male homosexuality is thought to be influenced by psycho-social factors, as well as having a genetic component. This is suggested by the high concordance of sexual orientation in identical twins and the fact that homosexuality is more common in males belonging to the maternal line of male homosexuals.
These effects have not been shown for female homosexuality, indicating that these two phenomena may have very different origins and dynamics.

Only the model of sexually antagonistic selection involving at least two genes – at least one of which must be on the X chromosome (inherited in males only through their mother) – accounted for all the known data. The results of this model show the interaction of male homosexuality with increased female fecundity within human populations, in a complex dynamic, resulting in the maintenance of male homosexuality at stable and relatively low frequencies, and highlighting the effects of heredity through the maternal line.

These findings provide new insights into male homosexuality in humans. In particular, they promote a focus shift in which homosexuality should not be viewed as a detrimental trait (due to the reduced male fecundity it entails), but, rather, should be considered within the wider evolutionary framework of a characteristic with gender-specific benefits, and which promotes female fecundity. This may well be the evolutionary origin of this genetic trait in human beings.

The possible widespread occurrence of sexually antagonistic characteristics in evolutionary processes, which play their evolutionary game by giving a fecundity benefit to one sex while disadvantaging the other, has only recently begun to be appreciated. Male homosexuality is just the first example of an unknown number of sexually antagonistic traits, which contribute to the maintenance of the natural genetic variability of humans.

An unexpected implication of the new models concerns the impact that the sexually antagonistic genetic factors for male homosexuality have on the overall fecundity of a population. The findings suggest that the proportion of male homosexuals may signal a corresponding proportion of females with higher fecundity. Consequently, these factors always contribute, all else being equal, a positive net increase of the fecundity of the whole population, when compared to populations in which such factors are lower or absent. This increase grows as the population baseline fecundity decreases; this means that the genes influencing male homosexuality end up playing the role of a buffer effect on any external factors lowering the overall fecundity of the whole population.

Source: Public Library of Science

Oct 9, 2009

Flu H1N1 2009 - Measures in school settings

GENEVA -- WHO is today issuing advice on measures that can be undertaken in schools to reduce the impact of the H1N1 influenza pandemic. Recommendations draw on recent experiences in several countries as well as studies of the health, economic, and social consequences of school closures. These studies were undertaken by members of a WHO informal network for mathematical modelling of the pandemic.

Experience to date has demonstrated the role of schools in amplifying transmission of the pandemic virus, both within schools and into the wider community. While outbreaks in schools are clearly an important dimension of the current pandemic, no single measure can stop or limit transmission in schools, which provide multiple opportunities for spread of the virus.

WHO recommends the use of a range of measures that can be adapted to the local epidemiological situation, available resources, and the social role played by many schools. National and local authorities are in the best position to make decisions about these measures and how they should be adapted and implemented.

WHO continues to recommend that students, teachers, and other staff who feel unwell should stay home. Plans should be in place, and space made available, to isolate students and staff who become ill while at school.

Schools should promote hand hygiene and respiratory etiquette and be stocked with appropriate supplies. Proper cleaning and ventilation and measures to reduce crowding are also advised.

School closures and class suspensions

Decisions about if and when schools should be closed during the pandemic are complex and highly context-specific. WHO cannot provide specific recommendations for or against school closure that are applicable to all settings. However, some general guidance comes from recent experience in several countries in both the northern and southern hemispheres, mathematical modelling, and experience during seasonal epidemics of influenza.

School closure can operate as a proactive measure, aimed at reducing transmission in the school and spread into the wider community. School closure can also be a reactive measure, when schools close or classes are suspended because high levels of absenteeism among students and staff make it impractical to continue classes.

The main health benefit of proactive school closure comes from slowing down the spread of an outbreak within a given area and thus flattening the peak of infections. This benefit becomes especially important when the number of people requiring medical care at the peak of the pandemic threatens to saturate or overwhelm health care capacity. By slowing the speed of spread, school closure can also buy some time as countries intensify preparedness measures or build up supplies of vaccines, antiviral drugs, and other interventions.

The timing of school closure is critically important. Modelling studies suggest that school closure has its greatest benefits when schools are closed very early in an outbreak, ideally before 1% of the population falls ill. Under ideal conditions, school closure can reduce the demand for health care by an estimated 30–50% at the peak of the pandemic. However, if schools close too late in the course of a community-wide outbreak, the resulting reduction in transmission is likely to be very limited.

Policies for school closure need to include measures that limit contact among students when not in school. If students congregate in a setting other than a school, they will continue to spread the virus, and the benefits of school closure will be greatly reduced, if not negated.

Economic and social costs

When making decisions, health officials and school authorities need to be aware of economic and social costs that can be disproportionately high when viewed against these potential benefits.

The main economic cost arises from absenteeism of working parents or guardians who have to stay home to take care of their children. Studies estimate that school closures can lead to the absence of 16% of the workforce, in addition to normal levels of absenteeism and absenteeism due to illness. Such estimates will, however, vary considerably across countries depending on several factors, including the structure of the workforce.

Paradoxically, while school closure can reduce the peak demand on health care systems, it can also disrupt the provision of essential health care, as many doctors and nurses are parents of school-age children.

Decisions also need to consider social welfare issues. Children’s health and well-being can be compromised if highly beneficial school-based social programmes, such as the provision of meals, are interrupted or if young children are left at home without supervision.

Oct 7, 2009

Genetic testing for breast or ovarian cancer risk may be greatly underutilized

Although a test for gene mutations known to significantly increase the risk of hereditary breast or ovarian cancer has been available for more than a decade, a new study finds that few women with family histories of these cancers are even discussing genetic testing with their physicians or other health care providers.

In a report in theJournal of General Internal Medicine, which has been released online, investigators from the Massachusetts General Hospital (MGH) Institute of Health Policy and Dana-Farber Cancer Institute note that their findings illustrate the challenges of bringing genetic information into real-world clinical practice. "Testing for BRCA1 and 2 mutations has been around a long time and should be a good indicator of whether genetic testing is making its way into regular medical practice," says Douglas Levy, PhD, of the MGH Institute for Health Policy, the study's lead author. "When a well-established genetic test is not being incorporated into clinical practice when appropriate, we are a long way from meeting the promise of personalized, genetically-tailored medical care.

"Most women's lifetime risk of breast cancer is about 13 percent, and the risk for ovarian cancer is less than 2 percent. But women with mutations in the BRCA1 or BRCA2 genes may be 3 to 7 times more likely to develop breast cancer and 9 to 30 times more likely to develop ovarian cancer than women with unaltered forms of the genes. Several organizations have issued clinical guidelines designating who should be screened for BRCA1/2 mutations, and while there have been discrepancies among the guidelines, all of them include a history of breast or ovarian cancer in close relatives among the criteria indicating elevated risk. The authors note that most U.S. health insurers cover at least part of the cost of BRCA1/2 testing for at-risk women.

Sep 8, 2009

New Genetic Variation Linked To Diabetes

Researchers say they have identified a genetic variation in people with type 2 diabetes that affects how the body's muscle cells respond to the hormone insulin. Previous studies have identified several genetic variations in people with type 2 diabetes that affect how insulin is produced in the pancreas. Today's study shows for the first time a genetic variation that seems to impair the ability of the body's muscle cells to use insulin to help them make energy.
People with type 2 diabetes can have problems with the body not producing enough insulin and with cells in the muscles, liver and fat becoming resistant to it. Without sufficient insulin, or if cells cannot use insulin properly, cells are unable to take glucose from the blood and turn it into energy. Until now, scientists had not been able to identify the genetic factors contributing to insulin resistance in type 2 diabetes. In the new research published in Nature Genetics, scientists from international institutions including Imperial College London, McGill University, Canada, CNRS, France, and the University of Copenhagen, Denmark, looked for genetic markers in over 14,000 people and identified four variations associated with type 2 diabetes. One of these was located near a gene called IRS1, which makes a protein that tells the cell to start taking in glucose from the blood when it is activated by insulin. The researchers believe that the variant they have identified interrupts this process, impairing the cells' ability to make energy from glucose. The researchers hope that scientists will be able to target this process to produce new treatments for type 2 diabetes. "It is now clear that several drugs should be used together to control this disease. Our new study provides scientists developing treatments with a straightforward target for a new drug to treat type 2 diabetes," said Froguel. The most significant of these variations was located near the insulin receptor substrate 1, or IRS1, gene.

Article: "A multistage genome-wide association study detects a new risk locus near IRS1 for type 2 diabetes, insulin resistance and hyperinsulinemia", Nature Genetics, 6 September 2009.

Aug 29, 2009

Attend Genetics Meetings for Free

Genetic Alliance is now accepting applications on a rolling basis for theirAdvocates Partnership Program. Successful applicants will have meeting registration fees waived plus be reimbursed for $250 in meeting-related fees, including transportation, hotel room, or airfare. Genetic Alliance will also arrange exclusive daily briefings.

The two meetings applicants can attend are:

American Society of Human Genetics Annual Meeting
October 20-24, Honolulu, Hawaii

National Society of Genetic Counselors Annual Education Conference
November 13-15, Atlanta, Georgia

Applicants are selected based on their responses to the following questions (for the ASHG meeting):

  1. What do you hope to gain from participating in the American Society of Human Genetics Annual Meeting? The Partnership Program?
  2. What are the main topics in the 2009 ASHG meeting program that interest you, and how will they benefit the work you are engaged in?
  3. What challenges do your organization and its members face with regard to research?
  4. What are the opportunities for your organization and its members in emerging research?
  5. Please describe the ways that genetics professionals are currently involved in your organization, or how you would like to involve them in the future.

Sounds like a fantastic opportunity especially for those who are based in the city where the meetings are going to be held this year. For more information and application forms, go tohttp://www.geneticalliance.org/advocates.opportunities.

Aug 19, 2009

The Next Big Thing Is Not Right in Front of You

Investing in technology-driven fields is risky, especially when everyone touts them as the Next Big Thing. Sure, it's easy to see quick gains, but you're just as likely to see those gains vanish as the next-generation technology sneaks in and replaces it -- the disruptor becomes the disrupted, so to speak.Perhaps the fastest evolving technology right now isn't computer tech, but rather is found in DNA sequencing. We've gone from sequencing the first genome for about $2.7 billion in the Human Genome Project just a few years ago and rather quickly come down to $50,000 apiece. Next stop: the $1,000 genome.This week an article in Nature Biotechnology documented the use of aHelicos BioSciences' system to sequence the genome of one of its scientific founders at a cost of under $50,000 -- excluding the cost of the $1 million machine, of course. In June, rival Illumina (Nasdaq: ILMN) announced that it was launching a service to sequence genomes of rich people -- let's face it, they're the only ones who can afford it at
this point -- for about the same cost, so the price isn't what's exciting.

What should have makers of second-generation sequencers -- Illumina, Roche and Life Technologies (Nasdaq: LIFE) -- a little worried is that Helicos' system allows for sequencing of a single DNA molecule. Removing the amplification step to generate many copies of the DNA molecule should speed up the process and theoretically make it less costly.Don't go running out to buy shares in Helicos just yet, though. There's a reason the company trades at a market cap well below $100 million. Two private companies, Oxford Nanopore and Pacific BioSciences, are developing machines that can sequence much longer single molecules, which should speed up sequencing and bring down the cost. Being private companies without disclosure issues, the businesses can operate somewhat in stealth mode, which makes it hard for investors to determine exactly who will win this battle. To keep from getting disrupted, Illumina has partnered with Oxford Nanopore to market its next-next-generation sequencer once it's available for commercial use, so it may be positioned well if Oxford Nanopore's technology turns out to work well.Is it nothing more than a head fake?

So calling the above the Next Big Thing is a bit of a mistake, mostly because we, as outside investors, don't have any real way to benefit (except, possibly, with Illumina). Rather than trying to figure out which company's technology will eventually prevail, investors might be better off looking at companies working on making the overload of information from sequencing thousands of genes more useful for patients: deCODE Genetics, Knome, Navigenics, and 23andMe.Unfortunately, they're all private companies, with the exception of deCODE Genetics. And that one is a penny stock selling off assets to stay alive. You can get a piece of 23andMe by buying shares in one of
its investors, Google (Nasdaq: GOOG), although that's a fairly convoluted way to get in on the action. Keep
them in mind for the future, though, if they ever go public. Presenting DNA sequence data in an understandable fashion is something customers are going to be willing to pay for. Fool co-founders Tom and David
Gardner used 23andMe's service, which eventually led David to recommend Illumina to Stock Advisor newsletter subscribers.The real beneficiaries of the Next Big Thing

So if the winner of the sequencer war is still up in the air (or they're all doomed to a low-margin death) and genome-information companies are all private, how can investors profit from this Next Big Thing? I think the real winners from low-priced sequencing will be drug developers.Consider: Much of the low-hanging fruit for treating diseases has already been picked. To take drug-development to the next level, drugmakers need to know how genetic differences in patients affect the usefulness of their drugs. For instance, mutations in a gene called K-ras affect whether Amgen's (Nasdaq:AMGN) Vectibix or Bristol-Myers Squibb's (NYSE: BMY) and Eli Lilly's (NYSE: LLY) Erbitux helps cancer patients or not. Knowing that ahead of time? Priceless, both to the patient and the company.By avoiding patients a drug can't help, drugs will become more efficient, on average, which should make everyone happy. However, a widespread personalized approach to medicine will only be possible when DNA sequencing become cheap enough. We seem to be on the road, but it will still take a while to develop drugs to take advantage of this new knowledge. So this is a long-term play for sure.The genome craze in the early part of this decade didn't live up to its hype -- just take a look at a 10-year chart ofHuman Genome Sciences (Nasdaq: HGSI) to see what I mean.I truly think it's different this time. But figuring out the best place to put your dollars to work requires more than jumping in on the obvious.

Aug 17, 2009

Biopolis Street, Singapore: how will it change your life?

One of the coolest places in Singapore – Biopolis, centre for biomedical sciences in Asia.

IMG_2768

IMG_2766

The Genome building houses swissnex Singapore (previously Swiss House Singapore) and the Genome Institute of Singapore.

Aug 15, 2009

Is cancer genetic?

Cancer risk is complex. Cancer is so common that we all probably know someone whose life has been affected by one form of cancer or another. A lot of us probably know people who seem to have cancer "running in the family". Cancer can occur in three main ways:

  • Sporadic cancers - these are cancers that occur by chance in individuals who have no known genetic risk factors and no significant family history. Approximately 60% of cancers are sporadic.

  • Familial cancers - these are cancers caused by variants in multiple genes and the environment all working together. In this case, each genetic variant causes a slight increase in risk. The overall risk of developing cancer depends on the number of cancer risk genetic variants that a person inherits and what environmental factors interact with those genes. Although these cancers appear to cluster in families, they don’t follow the typical rules of inheritance.

  • Hereditary cancers - these are cancers that are associated with a change in a single cancer susceptibility gene (like BRCA1 or BRCA2). These genes account for a very small percentage of all cancers. In fact, only 5-10% of breast and colon cancer cases are caused by changes in a single gene. Although everyone who carries a change in a cancer susceptibility gene does not get cancer, the risk is increased greatly, usually to 50% or higher. These types of genetic changes are passed on in an autosomal dominant inheritance pattern in families. This means that each child of an individual that carries a gene change in a hereditary cancer susceptibility gene has a 50% chance of inheriting the gene change.

Many people mistakenly think that the risk of cancer is always passed on through families as a single "cancer gene". However, like other complex diseases, changes in many genes that each plays a role in the development of cancer are much more likely to be the cause of familial cancer than a change in a single gene.

The testing that is provided as part of participation in the Coriell Personalized Medicine Collaborative™ study will look at gene changes that contribute to an individual's risk of cancer but WILL NOT look for single genes, such as BRCA1 or BRCA2, known to cause hereditary breast and ovarian cancers or other genes known to cause other hereditary cancer syndromes. If you believe you are at risk of a hereditary cancer syndrome please discuss this with your doctor or a genetic counselor.

nheriting a "cancer gene" does NOT mean you will get cancer

Having a genetic variant associated with cancer does NOT mean that you will definitely get cancer. A genetic variant associated with cancer is simply another risk factor. Just as non-genetic risk factors like smoking or diet impact your overall cancer risk, genetic variants also influence your risk of developing cancer. Knowing that you have a genetic risk and understanding what it means may motivate you to make preventive lifestyle and behavioral changes. It may also encourage you to ask your doctor about other ways to help lower your risk.

Genetic changes can influence cancer treatment

drugs









Treatment for cancer is very complex. Two patients with the same type of cancer may respond very differently to the same treatment. While some genes are involved in the risk to develop cancer, other genes are involved in the way our body responds to medicine. Researchers have found gene changes that are associated with a better or worse response to certain cancer-fighting drugs. The CPMC research study hopes to gain a better understanding of the genetic variants that play a role in drug response so that this information can be used to improve the treatment of cancer and other diseases.

Jul 17, 2009

GENE POLYMORPHISMS AND GLIOMA RISK

July 9, 2009 — An international study of genetic variations involved in glioma, the most frequently occurring type of brain tumor, has identified 14 common gene variants in 5 genes associated with the occurrence of glioma.

Published online July 5 in Nature Genetics, the international investigation, led by researchers at the M.D. Anderson Cancer Center in Houston, Texas, analyzed data from 2 genomewide association studies from the United States and the United Kingdom. Together, the studies included 1878 patients with glioma and 3670 control individuals whose genotypes were obtained. "It's the first time we've had a large enough sample to understand the genetic risk factors related to glioma," said one of the senior authors, Melissa Bondy, PhD, professor, Department of Epidemiology, M.D. Anderson Cancer Center, University of Texas, in an M.D. Anderson press release.

The study contributes to understanding the possible cause of this common type of brain tumor, which constitutes approximately 80% of all primary brain malignancies. The only contributing factor identified previously was ionizing radiation. However, an increased familial risk had been recognized, leading to the US and UK genomewide association studies of glioma in populations with Western European heritage. Beginning with the genotyping of more than a half-million single nucleotide polymorphisms (SNPs), the researchers found 34 SNPs demonstrating strong evidence of association with glioma (P <>−5). Replication studies were carried out in 3 case-control groups from French, German, and Swedish populations, totaling 2545 patients with glioma and 2953 control individuals.

Combined results from genomewide association and replication studies pointed to 14 SNPs in 5 genes that qualified for genomewide significance (P <>−7). Among these 14 SNPs, the 95% odds ratios (ORs) ranged from 1.18 to 1.36, with respective Pvalues ranging from 1.07 × 10−8 to 2.34 × 10-18. The 5 genes implicated were TERT,CCDC26, CDKN2A/B, PHLDB1, and RTEL1. The strongest association was found for a SNP in CCDC26, a gene on chromosome 8 that influences retinoic acid, thus reducing telomerase activity and increasing programmed cell death. A SNP in TERT showed the next strongest association with glioma (P = 1.50 × 10−17). TERT is necessary for telomerase activity and maintaining telomeres.

The third strongest association (P = 7.24 × 10−15) was for a SNP in CDKN2B. TheCDKN2A/B region activates p53, a well-known tumor suppressor. Interestingly, half of all brain tumors have lost at least 1 copy of this gene — a deficit that usually indicates poor prognosis. The fourth-ranked SNP (P = 2.52 × 10−12) was located inRTEL1, a gene on chromosome 20 that normally functions to stabilize the genome. The fifth strongest signal (P = 1.07 × 10−8) was demonstrated for a SNP in PHLDB1— a gene previously implicated in neuroblastoma, but not in glioma. The only interactive effects detected in the study were between SNPs in CDCC26, and analysis of other pairs showed that their effects on glioma were independent. As rank-ordered here by their strength of association with glioma, the 5 genes increased the risk for glioma by 36%, 27%, 24%, 28%, and 18%, respectively.

Because their effects are largely independent, the variants' contributions to glioma risk are additive: "Individuals with eight or more risk alleles have an approximately fourfold increase in glioma risk compared to those with a median number of risk alleles," the report stated. However, this may be a low estimate because the model weighted the SNPs equally, which is unlikely in reality. At present, the authors caution against using the results of their study for individual screenings. Not only is more research needed on the function of the individual genes, but factors such as demographics, environmental factors, and lifestyle should be included when identifying at-risk individuals.

The investigators will begin an even more comprehensive study next year, enrolling 6000 patients with glioma and 6000 control individuals. "We will be able to look at all of the potential risk and protective factors we've identified in much smaller studies over the years," said Dr. Bondy, "such as exposure to ionizing radiation, allergies, infections, and use of nonsteroidal anti-inflammatory drugs." Dr. Bondy is also optimistic about the future: "Our findings give reasons for hope for those who might be affected and an incentive for a more comprehensive investigation of what has been a mysterious disorder."

Nat Genet. Published online July 5, 2009.

Jun 3, 2009

Simple genetic test determines transplant drug tolerance

A simple genetic test can determine a kidney transplant patient's tolerance for a potent anti-rejection medication, according to an upcoming study in the Journal of the American Society Nephrology (JASN). The test could allow doctors to individualize each patient's dose, optimizing the drug's benefits and minimizing its side effects.

Cyclosporine A is an important immunosuppressant therapy for individuals who receive kidney transplants - without it, many patients would experience organ rejection and would not survive. Unfortunately, cyclosporine A can cause serious side effects such as elevated blood pressure, increased risk of infections and cancers, and kidney function deterioration. The frequency and severity of cyclosporine A-related side effects vary among patients, even at comparable cyclosporin A levels in the blood. Determining which patients are more sensitive than others is a challenge for physicians who prescribe the medication.

Giuseppe Remuzzi, MD, FRCP, and Piero Ruggenenti, MD (Mario Negri Institute for Pharmacological Research, Italy), and their colleagues, hypothesized that genetics may influence patients' susceptibilities to cyclosporine A's side effects. In particular, they suspected that variations in a gene called ABCB1, which creates a protein that transports drugs out of cells, may play a role. In individuals who have certain genetic changes in the ABCB1 gene, the transporting protein is sluggish so that when a drug is present, it lingers within cells and tissues. This can amplify the drug's effects.

After studying the genetics of 147 kidney transplant recipients, the researchers found that patients with these genetic changes in the ABCB1 gene were more likely to experience side effects after receiving cyclosporine A than patients without the variants. These effects included delayed functioning of the transplanted kidney, increased need for anti-hypertensive medications, and the development of diabetes, infections, and cancers.

"The identification of particular genetic variants performed before transplantation, while patients are on the waiting list, could provide useful information to tailor cyclosporine A dose as early as possible after transplantation, with the ultimate goal to decrease toxicity, improve efficacy, and increase long-term graft survival," said Dr. Remuzzi.The authors report no financial disclosures.

The article, entitled "ABCB1 Genotypes Predict Cyclosporine-Related Adverse Events and Kidney Allograft Outcome," will appear online at http://jasn.asnjournals.org/ on May 21, 2009, doi 10.1681/ASN.2008080819.
http://www.asn-online.org/

May 5, 2009

Deficit apprendimento: responsabili nove geni.

Una collaborazione di più di 70 ricercatori di tutto il mondo ha scoperto nove nuovi geni sul cromosoma X che, quando silenziati, sono responsabili di un deficit di apprendimento. La prevalenza delle difficolta’ di apprendimento ammonta a circa il 2 per cento della popolazione generale e  tali disturbi sono piu’ diffusi nei soggetti maschi che nelle femmine. Nello studio, sono stati sequenziati circa 720 dei circa 800 geni che compongono il cromosoma X, a partire da campioni ricavati da individui appartenenti a 208 famiglie a cui sono stati diagnosticati problemi di apprendimento.

Leggi abstract:

Michael R Stratton, et al

GeneBright offers genetic analysis of cognitive attitudes, check www.genebright.com

Apr 22, 2009

Genetic Risk Prediction — Are We There Yet?

(from Peter Kraft, Ph.D., and David J. Hunter, M.B., B.S., Sc.D., M.P.H. - New England Medical Journal)

a major goal of the Human Genome Project was to facilitate the identification of inherited genetic variants that increase or decrease the risk of complex diseases. The completion of the International HapMap Project and the development of new methods for genotyping individual DNA samples at 500,000 or more loci have led to a wave of discoveries through genomewide association studies. These analyses have identified common genetic variants that are associated with the risk of more than 40 diseases and human phenotypes. Several companies have begun offering direct-to-consumer testing that uses the same single-nucleotide polymorphism chips that are used in genomewide association studies. These companies claim that such testing should be made available to consumers who are interested in their personal level of risk for the relevant diseases. Now, “risk tests” for specific diseases such as breast cancer are also being marketed to physicians and consumers. 
The availability of highly predictive and reasonably affordable tests of genetic predisposition to important diseases would have major clinical, social, and economic ramifications. But the great majority of the newly identified riskmarker alleles confer very small relative risks, ranging from 1.1 to 1.5, even though such analyses meet stringent statistical criteria (i.e., the identification of associations with disease that have very small P values and hence are unlikely to be false positives). However, even when alleles that are associated with a modest increase in risk are combined, they generally have low discriminatory and predictive ability. 
One argument in favor of using the available genetic predictors is that some information must be better than no information, and we should not let the perfect be the enemy of the good by refusing to make use of our knowledge until it is more complete. Why not begin testing for common genetic variants whose associations with susceptibility to disease have been established? The answer lies in the stability of the current risk estimates. 
The good news is that pooling the results of multiple genomewide association studies has led to increased statistical power and the discovery of many new loci linked to small increases in the risks of major diseases and phenotypes. For example, pooling efforts have led to the identification of more than 16 new loci associated with diabetes and more than 30 loci linked to Crohn’s disease. From a scientific perspective, we would like to know roughly how many risk loci remain to be discovered. From a clinical and policy perspective, we would like to know the extent to which the available associations are useful for measuring risk, both in absolute terms and relative to the expanded set of associations that are likely to be discovered in the next few years. 
Although we know of many more risk loci than we did 2 years ago, there are probably many more associations that are yet to be discovered for these complex diseases. Less common variants in the prevalence range of 0.5 to 5.0% also remain to be discovered. Estimates of risk based on established locus associations are therefore likely to change substantially in the next few years. But this is only one of the factors determining whether knowledge of genetic risk is beneficial. The clinical value of a genetic test also depends on its sensitivity, specificity, and positive and negative predictive values; the costs and benefits of interventions; and the availability of data linking specific variants to improved clinical outcomes. In particular, although we will be better able to distinguish subtle differences in risk as we discover more risk loci, most people will still be at or near the median level of risk. As a result, for less-common diseases (with a prevalence of 1% or less), the positive predictive value of a genetic test will almost always be low. 

We are still too early in the cycle of discovery for most tests that are based on newly discovered associations to provide stable estimates of genetic risk for many diseases. Although the major findings are highly unlikely to be false positives, the identified variants do not contribute more than a small fraction of the inherited predisposition. Once risk estimates are more stable, the usefulness of genetic screening will need to be considered for each disease, and recommendations about potential interventions will need to be made for persons whose predicted risk exceeds some threshold. Appropriate guidelines are urgently needed to help physicians advise patients who are considering this form of genetic testing as to how to interpret, and when to act on, the results as they become more stable.

(sent by M Cesco Gaspere)

Apr 17, 2009

A 10-step guide to genetic testing

What is genetic testing? A type of medical test that identifies changes in the DNA. Tests can target gene mutations or variations of single nucleotides and can be used in diagnostic to find changes associated with inherited disorders or as a prevention to assess the risk in developing a certain disease. The results of the test can confirm or rule out a suspected genetic condition or help determine a person’s chance of developing or passing on a genetic disorder.

What are the types of genetic tests? Genetic testing can provide information about a person’s genes and chromosomes. Available types of testing include:

·        Newborn screening – used just after birth to identify genetic disorders that can be treated early in life.

·        Diagnostic testing – used to identify or rule out a specific genetic or chromosomal condition.

·        Prevention testing – offered to individuals who have a family history of a genetic disorder and to people in certain ethnic groups with an increased risk of specific genetic conditions.

·        Prenatal testing – used to detect changes in a foetus’s genes or chromosomes before birth. It is offered during pregnancy if there is an increased risk that the baby will have a genetic or chromosomal disorder.

·        Preimplantation testing – preimplantation genetic diagnosis (PGD), used to detect genetic changes in embryos created using assisted reproductive techniques.

·        Predictive and presymptomatic testing – used to detect gene mutations associated with disorders that appear later in life. Can be helpful to people with a family member with a genetic disorder, but who have no features of the disorder themselves at the time of testing. Predictive testing can identify mutations that increase a person’s risk of developing disorders with a genetic basis, such as certain types of cancer.

·        Forensic testing – uses DNA sequences to identify an individual for legal purposes.

How is genetic testing done? Genetic tests are performed on a sample of blood, hair, skin, amniotic fluid (the fluid that surrounds a foetus during pregnancy), or other tissue. The sample is sent to a laboratory where technicians look for specific changes in chromosomes, DNA, or proteins, depending on the suspected disorder. The laboratory reports the test results in writing to a person’s doctor or genetic counsellor.

What do the results of genetic tests mean? The results of genetic tests are not always straightforward, therefore it is important for patients and their families to ask questions about the potential meaning of genetic test results both before and after the test is performed. When interpreting test results, healthcare professionals consider a person’s medical history, family history, and the type of genetic test that was done. It is important to note that a positive result of a predictive or presymptomatic genetic test usually cannot establish the exact risk of developing a disorder.

What is the cost of genetic testing, and how long does it take to get the results? It can range from under $200 to more than $2000 (US Dollars), depending on the nature and complexity of the test. From the date that a sample is taken, it may take a few weeks to a few months to receive the test results. The doctor or genetic counsellor who orders a particular test can provide specific information about the cost and time frame associated with that test.

Will health insurance cover the costs of genetic testing? In many cases, health insurance plans will cover the costs of genetic testing when it is recommended by a person’s doctor. Health insurance providers have different policies about which tests are covered. A person interested in submitting the costs of testing may wish to contact his or her insurance company beforehand to ask about coverage.

What are the benefits of genetic testing? Genetic testing has potential benefits whether the results are positive or negative for a gene mutation. Test results can provide a sense of relief from uncertainty and help people make informed decisions about managing their health care. A negative result can eliminate the need for unnecessary checkups and screening tests in some cases; a positive result can direct a person toward available prevention, monitoring, and treatment options.

What are the risks and limitations of genetic testing? The physical risks associated with most genetic tests are very small, particularly for those tests that require only a blood sample or buccal smear. Most of the risks associated with genetic testing involve the emotional, social, or financial consequences of the test results. Genetic testing can provide only limited information about an inherited condition. The test often can’t determine if a person will show symptoms of a disorder, how severe the symptoms will be, or whether the disorder will progress over time. Another limitation is the lack of treatment strategies for many genetic disorders once they are diagnosed. A genetics professional can explain in detail the benefits, risks, and limitations of a particular test.

What is genetic discrimination? There is no risk of genetic discrimination when people undergo genetic testing by their employer or insurance company due to the G.I.N.A.

How does genetic testing in a research setting differ from clinical genetic testing? The main differences are the purpose of the test and who receives the results. The goals of research testing include finding unknown genes, learning how genes work, and advancing our understanding of genetic conditions. The results of these testing are usually not available to patients or their healthcare providers. Clinical testing is done to find out about an inherited disorder in an individual patient or family. People receive the results of their tests and can use them to make decisions about medical care or reproductive issues. Clinical and research testing must both involve a process of informed consent in which patients learn about the testing procedure, the risks and benefits of the test, and the potential consequences of testing.